We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

2875:TSEToyo Suisan Kaisha, Ltd. Analysis

Data as of 2026-06-14 - not real-time

¥9,846.00

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Toyo Suisan Kaisha, Ltd. is trading at roughly ¥9,846, a price that sits just above the computed support level of ¥9,789 and well below the analyst consensus target median of ¥12,300, indicating a clear price discount. Technical indicators reinforce this view: the 20‑day SMA of ¥10,639 and 50‑day SMA of ¥10,762 both sit above the market price, while the 200‑day SMA of ¥10,836 suggests the stock is still below its longer‑term average. The RSI of 29.5 places the equity in oversold territory, and the MACD histogram is deeply negative (‑87.5) with a bearish signal line, confirming short‑term downward momentum. Nevertheless, the company’s fundamentals remain solid: a forward PE of about 15×, a price‑to‑book of 1.8×, and a dividend yield near 2.2% with a modest payout ratio of roughly 30% indicate reasonable valuation and cash flow coverage. The balance sheet shows a low debt‑to‑equity of 0.60 and ample cash (¥261.8 bn) relative to debt (¥3.3 bn), supporting dividend sustainability.
Recent material news highlights a shareholder proposal for a ¥36 bn share‑repurchase aimed at accelerating the board’s 15% ROE target, which could tighten the capital structure and provide a modest upside catalyst. However, the stock’s 30‑day volatility of about 24% and a max drawdown of –20% underscore notable price swing risk, especially given the low beta (~0.24) that limits market‑wide hedging benefits.
In summary, the equity appears undervalued relative to consensus targets, with a fair valuation grade, sustainable dividend coverage, but carries medium‑level risk from price volatility and sector‑specific defensive dynamics.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • price near technical support
  • oversold RSI
  • bearish MACD signal

Medium Term

1–3 years
Neutral
Model confidence: 7/10

Key Factors

  • fair PE relative to peers
  • stable dividend yield
  • low debt‑to‑equity

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • price discount to consensus target
  • share‑repurchase upside catalyst
  • sustainable cash flow and dividend

Key Metrics & Analysis

Financial Health

Revenue Growth19.20%
Profit Margin13.08%
P/E Ratio13.8
ROE13.59%
ROA8.66%
Debt/Equity0.60
P/B Ratio1.8
Op. Cash Flow¥85.2B
Free Cash Flow¥18.0B

Technical Analysis

TrendBearish
RSI29.5
Support¥9,789.00
Resistance¥11,325.00
MA 20¥10,639.35
MA 50¥10,762.64
MA 200¥10,836.17
MACDBearish
VolumeStable
Fear & Greed Index89.86

Valuation

Fair Value¥8,024.64
Target Price¥12,109.09
Upside/Downside22.98%
GradeUndervalued
TypeBlend
Dividend Yield2.23%

Risk Assessment

Beta0.01
Volatility24.21%
Sector RiskLow
Reg. RiskLow
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.